Objective: Study on effects of Salvia officinalis L. leaf extract in treatment of hyperlipidemic type 2 diabetic patients. Study population: Hyperlipidemic type 2 diabetic patients attending the diabetes clinic. Sample size: 60 patients. Inclusion criteria: Iranian male and female type 2 diabetic outpatients, patients aged 40 to 60 years, patients with fasting serum glucose levels from 150 mg/dLto 200 mg/dL, patients with blood HbA1c levels from 7% to 9% despite taking two 5 mg glyburide tablets and two 500 mg metformin tablets every day, patients using two 5 mg glyburide tablets and two 500 mg metformin tablets every day, patients with fasting serum LDL levels from 100 mg/dL to 150 mg/dL and/or patients with fasting triglyceride levels from 200 mg/dL to 300 mg/dL. Exclusion criteria: Patients taking other anti-hyperglycemic and anti-hyperlipidemic agents, patients receiving insulin, patients with cardiac, renal, hepatic, hematological diseases, hypothyroidism, tachycardia, vertigo and seizure, patients with a history of gallstones or gall bladder surgery, patients using estrogen, steroid, beta-blocker and thiazide, pregnant women, women planning pregnancy, breast-feeding women. Intervention: The sage leaf extract is administered to a group of about 30 patients at the dose of one 500 mg capsule every 8 hours for 3 months and one placebo capsule is administered to another group of about 30 patients every 8 hours for3 months. At the end of the study, the blood levels of fasting glucose, glycosylated hemoglobin, lipids, creatinine and hepatic enzymes of the patients in the drug group and the placebo group are determined and compared with each other.